title: Prognostic implications of cytogenetic findings in kidney cancer.
abstract: OBJECTIVE
  To evaluate the prognostic impact of cytogenetic findings in renal cell carcinoma (RCC).
  
  
  METHODS
  Tumour cytogenetics, histomorphology, DNA ploidy and S-phase fraction, stage, size, and grade were related to survival in 50 consecutive patients with RCC. The mean follow-up was 3.9 years (median 4.2, range 0-8.8).
  
  
  RESULTS
  The predictive probability for recurrence-free survival at 5 years (5-year RFS) for all 50 patients was 0.54. There was a significant association between the degree of cytogenetic complexity and survival, in that patients with five or less aberrations had a better prognosis than those with more than five changes (5-year RFS 0.71 and 0.43, respectively; P < 0.05). Patients with del(8p)/-8, +12, and +20 had a significantly worse prognosis compared with those without these aberrations. Of the well-known prognostic variables grade and stage, the former was far better for predicting prognosis. A Spearman correlation test showed a significant covariation of grade with the S-phase fraction, T-stage, and cytogenetic complexity.
  
  
  CONCLUSIONS
  The degree of cytogenetic complexity and recurrent cytogenetic abnormalities affect the prognosis in RCC, although grade was the most reliable independent prognostic factor predicting disease recurrence.
authors.affiliation: Department of Clinical Genetics, University Hospital, Lund, Sweden.
authors.forename: P
authors.initials: P
authors.lastname: Elfving
authors.forename: N
authors.initials: N
authors.lastname: Mandahl
authors.forename: R
authors.initials: R
authors.lastname: Lundgren
authors.forename: J
authors.initials: J
authors.lastname: Limon
authors.forename: E
authors.initials: E
authors.lastname: Bak-Jensen
authors.forename: M
authors.initials: M
authors.lastname: Fernö
authors.forename: H
authors.initials: H
authors.lastname: Olsson
authors.forename: F
authors.initials: F
authors.lastname: Mitelman
mesh_terms: D002292:Carcinoma, Renal Cell / Q000235:genetics* / Q000401:mortality / Q000473:pathology*; D002869:Chromosome Aberrations; D018572:Disease-Free Survival; D005434:Flow Cytometry; D005500:Follow-Up Studies; D006801:Humans; D007680:Kidney Neoplasms / Q000235:genetics* / Q000401:mortality / Q000473:pathology*; D015999:Multivariate Analysis; D009362:Neoplasm Metastasis; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D011003:Ploidies; D011379:Prognosis; D016196:S Phase; D015996:Survival Rate; D013997:Time Factors